Effects of a Zumba Dance Program for Postmenopausal Women With Metabolic Syndrome

Metabolic Syndrome Clinical Trial

— ZumBeat  

Official title:

ZumBeat: Effekte Eines Rhythmusorientierten Aeroben Tanz-Bewegungsprogrammes für Postmenopausale Frauen Mit Metabolischem Syndrom

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02384694
• Other study ID #: EKNZ 2014-033
• Status: Completed
• Phase: N/A
• First received: February 27, 2015
• Last updated: March 4, 2015
• Start date: May 2014
• Est. completion date: October 2014

Study information

• Verified date: March 2015
• Source: University of Basel
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to examine the effects of a 12-week Zumba dance intervention on fitness, anthropometric and psychometric parameters and eating behavior.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 45 Years to 65 Years

Eligibility

Inclusion Criteria:

• postmenopausal women (Age 45-65)

• waist of >94 cm or BMI > 30kg/m2

• not physically active >1x/week for 20 minutes

• written consent before the start of the study

Exclusion Criteria:

• involvement in other clinical studies

• unable to participate at the dance lessons

• medical contraindications for the intervention or increased risk for exercise participation

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X

Intervention

Other:
• Zumba dance
Twelve weeks, 3 times weekly 1 hour training

Locations

Country	Name	City	State
Switzerland	Department for Sports, Exercise and Health, Sports and Exercise Medicine, University of Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University of Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VO2peak (=peak oxygen consumption)	The VO2peak will be assessed for every participant during a treadmill spirometry at baseline and follow-up using a mask and calibrated gas measuring devices applying a standardized protocol.	VO2peak will be assessed at T1 and T12 (baseline and after 12 weeks of intervention)	No